Synthesis of Nitro Esters of Prednisolone, New Compounds Combining Pharmacological Properties of Both Glucocorticoids and Nitric Oxide

Journal of Medicinal Chemistry

Volumn 47, Issue 3, 2004, Pages 711-719

  Baraldi, Pier Giovanni ^a   Romagnoli, Romeo ^a   Nuñez, Maria Del Carmen ^a   Perretti, Mauro ^c   Paul Clark, Mark J ^c   Ferrario, Massimiliano ^b   Govoni, Mirco ^b   Benedini, Francesca ^b   Ongini, Ennio ^b  

^a UNIVERSITY OF FERRARA   (Italy)

^b Nicox Research Institute   (Italy)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOIC ACID DERIVATIVE; DEXAMETHASONE; ESTER DERIVATIVE; GLUCOCORTICOID RECEPTOR; HYDROXYL GROUP; NCX 1015; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; PREDNISOLONE; TRITIUM; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BROMINATION; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ESTERIFICATION; FREEZE DRYING; HUMAN; HUMAN CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ELECTRON SPIN RESONANCE SPECTROSCOPY; ESTERS; GLUCOCORTICOIDS; HUMANS; INFLAMMATION; LEUKOCYTES, MONONUCLEAR; MICE; NITRIC OXIDE; NITRIC OXIDE DONORS; NITRO COMPOUNDS; PREDNISOLONE; RATS; RECEPTORS, GLUCOCORTICOID; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 1642458670     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030964b     Document Type: Article

References (26)

1. Schimmer, B. P.; Parker, K. L. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogues; inhibitors of the synthesis and actions of adrenocortical hormones. In The Pharmacological Basis of Therapeutics, 10th ed.; Gilman, A. G., Goodman, L. S., Rall, T. W., Murad, F., Eds.; Macmillan Publishing Co.: New York, 2001; pp 1649-1677.
2. Schäcke, H.; Döcke, W. D.; Asadullah, K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol. Ther. 2002, 96, 23-43.
3. Necela, B. M.; Cidlowski, J. A. Crystallization of the human glucocorticoid receptor ligand binding domain: a step towards selective glucocorticoids. Trends Pharmacol. Sci. 2003, 24, 58-61.
4. Coghlan, M. J.; Elmore, S. W.; Kym P. R.; Kort M. E. Selective Glucocorticoid Receptor Modulators. Annu. Rep. Med. Chem. 2002, 37, 167-176.
5. Wallace, J. L.; Soldato, P. D. The therapeutic potential of NO-NSAIDs. Fundam. Clin. Pharmacol. 2003, 17, 11-20.
6. Keeble, J. E.; Moore, P. K. Pharmacology and potential therapeutic applications of nitric oxide-releasing nonsteroidal antiinflammatory and related nitric oxide-donating drugs. Br. J. Pharmacol. 2002, 137, 295-310.
7. Chiroli, V.; Benedini, F.; Ongini, E.; Del Soldato, P. Nitric oxide-donating nonsteroidal antiinflammatory drugs: the case of nitroderivatives of aspirin. Eur. J. Med. Chem. 2003, 38, 441-446.
8. Moncada, S.; Palmer, R. M.; Higgs, E. A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 1991, 43, 109-142.
9. Wallace, J. L.; Ignarro, L. J.; Fiorucci, S. Potential cardioprotective actions of no-releasing aspirin. Nat. Rev. Drug. Discovery 2002, 1, 375-382.
10. Hinton, I. G.; Mann, F. G.; Vanterpool, A. Interaction of o-chloromethylphenacyl chloride and primary amines: a novel formation of the isoindoline system. J. Chem. Soc. 1959, 610-614.
11. Ambler, J.; Brown, L.; Cockcroft, X. L.; Grutter, M.; Hayler, J.; Janus, D.; Jones, D.; Kane, P.; Menear, K.; Priestle, J.; Smith, G.; Talbot, M.; Walker, C. V.; Wathey, B. Optimisation of the P2 pharmacophore in a series of thrombin inhibitors: ion-dipole interactions with lysine 60G. Bioorg. Med. Chem. Lett. 1999, 9, 1317-1322.
12. Egbertson, M. S.; Chang, C. T.; Duggan, M. E.; Gould, R. J.; Halczenko, W.; Hartman, G. D.; Laswell, W. L.; Lynch, J. J., Jr.; Lynch, R. J.; Manno, P. D.; Naylor, A. M.; Prugh, J. D.; Ramjit, D. R.; Sitko, G. R.; Smith, R. S.; Turchi, L. M.; Zhang, G. Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp. J. Med. Chem. 1994, 37, 2537-2551.
13. Brundish, D.; Bull, A.; Donovan, V.; Fullerton, J. D.; Garman, S. M.; Hayler, J. F.; Janus, D.; Kane, P. D.; McDonnell, M.; Smith, G. P.; Wakeford, R.; Walker, C. V.; Howarth, G.; Hoyle, W.; Allen, M. C.; Ambler, J.; Butler, K. ; Talbot, M. D. Design and synthesis of thrombin inhibitors: analogues of MD-805 with reduced stereogenicity and improved potency. J. Med. Chem. 1999, 42, 4584-4603.
14. Siegel, M. G.; Chaney, M. O.; Bruns, R. F.; Clay, M. P.; Schober, D. A.; Van Abbema, A. M.; Johnson, D. W.; Cantrell, B. E.; Hahn, P. J.; Hunden, D. C.; Gehlert, D. R.; Zarrinmayeh, H.; Ornstein, P. L.; Zimmerman, D. M.; Koppel, G. A. Rapid parallel synthesis applied to the optimization of a series of potent nonpeptide neuropeptide Y-1 receptor antagonists. Tetrahedron 1999, 55, 11619-11639.
15. Hromatka, O.; Engel, E. Triethylenediamine (1,4-diazabicyclo-[2.2.2]octane) II. Chem. Ber. 1943, 76B, 712-717.
16. Schliemann, W.; Buege, A.; Reppel, L. Studies on the synthesis of some 1-(p-fluorophenyl)-1-pyrid-2′-ylbutylamines. Pharmazie 1980, 35, 69-72.
17. Xue, C. B.; Roderick, J.; Jackson, S.; Rafalski, M.; Rockwell, A.; Mousa, S.; Olson, R. E.; DeGrado, W. F. Design, synthesis, and in vitro activities of benzamide-core glycoprotein IIb/IIIa antagonists: 2,3-diaminopropionic acid derivatives as surrogates of aspartic acid. Bioorg. Med. Chem. 1997, 5, 693-705.
18. Boschi, D.; Di Stilo, A.; Fruttero, R.; Medana, C.; Sorba, G.; Gasco, A. Alpha 1-adrenoceptor blocking activity of some ring-open analogues of prazosin. Arch. Pharm. (Weinheim, Germany) 1994, 327, 661-667.
19. Vallance, P.; Leiper, J.; Blocking NO synthesis: how, where and why? Nat. Rev. Drug Discovery 2002, 1, 939-950.
20. Carini, M.; Aldini, G.; Stefani, R.; Orioli, M.; Facino, R. M. Nitrosylhemoglobin, an unequivocal index of nitric oxide release from nitroaspirin: in vitro and in vivo studies in the rat by ESR spectroscopy. J. Pharm. Biomed. Anal. 2001, 26, 509-518.
21. Casini, A.; Scozzafava, A.; Mincione, F.; Menabuoni, L.; Ilies, M. A.; Supuran, C. T. Carbonic anhydrase inhibitors: water-soluble 4-sulfamoylphenylthioureas as topical intraocular pressure-lowering agents with long-lasting effects. J. Med. Chem. 2000, 43, 4884-4892.
22. Paul-Clark, M.; Del Soldato, P.; Fiorucci, S.; Flower, R. J.; Perretti, M. 21-NO-prednisolone is a novel nitric oxide-releasing derivative of prednisolone with enhanced antiinflammatory properties. Br. J. Pharmacol. 2000, 131, 1345-1354.
23. Fiorucci, S.; Antonelli, E.; Distrutti, E.; Del Soldato, P.; Flower, R. J.; Clark, M. J.; Morelli, A.; Perretti, M.; Ignarro, L. J. NCX-1015, a nitric-oxide derivative of prednisolone, enhances regulatory T cells in the lamina propria and protects against 2,4,6-trinitrobenzenesulfonic acid-induced colitis in mice. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 15770-15775.
24. Paul-Clark, M.; Mancini, L.; Del Soldato, P.; Flower, R. J.; Perretti, M. Potent antiarthritic properties of a glucocorticoid derivative, NCX-1015, in an experimental model of arthritis. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 1677-1682.
25. Peskar, B.; Maricic, N.; Ehrlich, K.; Swaka, N. NCX-1015, a novel nitric oxide-releasing derivative of prednisolone, combines potent antiinflammatory activity and low toxicity in the rat stomach subjected to ischemia-reperfusion. Gastroenterology 2002, 229 (Suppl. A), M-891 (abstr.)
26. Kosaka, H.; Sawai, Y.; Sakaguchi, H.; Kumura, E.; Harada, N.; Watanabe, M.; Shiga, T. ESR spectral transition by arteriovenous cycle in nitric oxide hemoglobin of cytokine-treated rats. Am. J. Physiol. 1994, 266, C1400-C1405.